.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The CRASH-2 randomized trial evaluated tranexamic acid in adults with significant traumatic bleeding or risk of significant bleeding. The study addressed a high-stakes surgical and trauma question: can an inexpensive antifibrinolytic reduce mortality when administered early after injury? The trial demonstrated a reduction in death due to bleeding among patients receiving tranexamic acid, with the greatest benefit associated with earlier treatment. The results helped establish tranexamic acid as a major component of modern trauma resuscitation pathways. For surgeons and trauma teams, the important lesson is timing. A therapy with a favourable evidence profile may lose benefit when treatment is delayed, making early recognition and protocolized administration crucial. CRASH-2 also illustrates how large pragmatic trials can rapidly change practice across very different healthcare settings. The clinical role of tranexamic acid still requires appropriate patient selection and integration into broader haemorrhage control. It does not replace definitive management of bleeding, damage-control surgery, transfusion support or correction of physiologic derangement. For ASICON's trauma training emphasis, CRASH-2 remains a useful evidence anchor: early, simple interventions can have major effects when incorporated into systematic trauma care.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The CRASH-2 randomized trial evaluated tranexamic acid in adults with significant traumatic bleeding or risk of significant bleeding. The study addressed a high-stakes surgical and trauma question: can an inexpensive antifibrinolytic reduce mortality when administered early after injury? The trial demonstrated a reduction in death due to bleeding among patients receiving tranexamic acid, with the greatest benefit associated with earlier treatment. The results helped establish tranexamic acid as a major component of modern trauma resuscitation pathways. For surgeons and trauma teams, the important lesson is timing. A therapy with a favourable evidence profile may lose benefit when treatment is delayed, making early recognition and protocolized administration crucial. CRASH-2 also illustrates how large pragmatic trials can rapidly change practice across very different healthcare settings. The clinical role of tranexamic acid still requires appropriate patient selection and integration into broader haemorrhage control. It does not replace definitive management of bleeding, damage-control surgery, transfusion support or correction of physiologic derangement. For ASICON's trauma training emphasis, CRASH-2 remains a useful evidence anchor: early, simple interventions can have major effects when incorporated into systematic trauma care.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
4 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
